Search Results - "Mary Ann Lukas, MD"

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome by O'Donoghue, Michelle L., MD, MPH, Braunwald, Eugene, MD, White, Harvey D., MD, Serruys, Patrick, MD, Steg, Ph. Gabriel, MD, Hochman, Judith, MD, Maggioni, Aldo P., MD, Bode, Christoph, MD, Weaver, Douglas, MD, Johnson, Joel L., PharmD, Cicconetti, Greg, PhD, Lukas, Mary Ann, MD, Tarka, Elizabeth, MD, Cannon, Christopher P., MD

“…Background Higher levels of lipoprotein-associated phospholipase A2 (Lp-PLA2 ) are associated with a higher risk of cardiovascular events and may play a causal…”
Get full text

A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients by Dunbar Ivy, MD, Maurice Beghetti, MD, Ernesto Juaneda-Simian, MD, PhD, Diane Miller, PhD, Mary Ann Lukas, MD, Chris Ioannou, PhD, Malek Okour, PhD, Jun Narita, MD, Rolf M.F. Berger, MD, PhD

“…Objective: To assess the safety and efficacy of the endothelin receptor antagonist ambrisentan in pediatric pulmonary arterial hypertension (PAH). Study…”
Get full text

Body Weight Changes with β-Blocker Use: Results from GEMINI by Messerli, Franz H., MD, Bell, David S.H., MB, Fonseca, Vivian, MD, Katholi, Richard E., MD, McGill, Janet B., MD, Phillips, Robert A., MD, PhD, Raskin, Philip, MD, Wright, Jackson T., MD, PhD, Bangalore, Sripal, MD, Holdbrook, Fred K., PhD, Lukas, Mary Ann, MD, Anderson, Karen M., PhD, Bakris, George L., MD

“…Abstract Purpose Patients with type 2 diabetes are commonly overweight, which can contribute to poor cardiovascular outcomes. β-blockers may promote weight…”
Get full text

Adherence With Once Daily Versus Twice Daily Carvedilol in Patients With Heart Failure: The Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients With Heart Failure (CASPER) Trial by Udelson, James E., MD, Pressler, Susan J., DNS, RN, Sackner-Bernstein, Jonathan, MD, Massaro, Joseph, PhD, Ordronneau, Paul, PhD, Lukas, Mary Ann, MD, Hauptman, Paul J., MD

“…Abstract Background Suboptimal compliance in taking guideline-based pharmacotherapy in patients with chronic heart failure (HF) potentially increases the…”
Get full text

β-Blocker dosing in community-based treatment of heart failure by Fowler, Michael B., MD, Lottes, Sandra R., PharmD, Nelson, Jeanenne J., PhD, Lukas, Mary Ann, MD, Gilbert, Edward M., MD, Greenberg, Barry, MD, Massie, Barry M., MD, Abraham, William T., MD, Franciosa, Joseph A., MD

“…Background Community patients with heart failure (HF) are older, less often treated by HF specialists, and have more comorbidity than those in randomized…”
Get full text

Comparison of Outcomes and Usefulness of Carvedilol Across a Spectrum of Left Ventricular Ejection Fractions in Patients With Heart Failure in Clinical Practice by Massie, Barry M., MD, Nelson, Jeanenne J., PhD, Lukas, Mary Ann, MD, Greenberg, Barry, MD, Fowler, Michael B., MD, Gilbert, Edward M., MD, Abraham, William T., MD, Lottes, Sandra R., PharmD, Franciosa, Joseph A., MD

“…Heart failure (HF) in the community differs meaningfully from that in clinical trials, particularly the higher prevalence of patients with preserved left…”
Get full text

Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) by Fonarow, Gregg C., MD, Lukas, Mary Ann, MD, Robertson, Michele, BSc, Colucci, Wilson S., MD, Dargie, Henry J., MD

“…Background In the CAPRICORN trial, carvedilol reduced all-cause mortality by 23% over a mean follow-up of 1.3 years in clinically stabilized post–myocardial…”
Get full text

The Safety of Amiodarone in Patients With Heart Failure by Torp-Pedersen, Christian, MD, Metra, Marco, MD, Spark, Philip, PhD, Lukas, Mary Ann, MD, Moullet, Christine, MD, Scherhag, Armin, MD, Komajda, Michel, MD, Cleland, John G.F., MD, Remme, Willem, MD, Di Lenarda, Andrea, MD, Swedberg, Karl, MD, Poole-Wilson, Philip A., MD

“…Abstract Background Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure. Methods and Results We randomized…”
Get full text

Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure by Remme, Willem J., MD, PhD, FACC, FAHA, FESC, Torp-Pedersen, Christian, MD, FESC, FACC, Cleland, John G.F., MD, FRCP, FESC, FACC, Poole-Wilson, Philip A., MD, FRCP, FESC, FACC, Metra, Marco, MD, Komajda, Michel, MD, PhD, FESC, Swedberg, Karl, MD, PhD, FESC, FACC, Di Lenarda, Andrea, MD, FESC, Spark, Phillip, BSc (Hons), Scherhag, Armin, MD, Moullet, Christine, MD, Lukas, Mary Ann, MD

“…Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET Willem J. Remme, Christian Torp-Pedersen, John G. F…”
Get full text